
Jianhui Yang
Articles
-
Jun 30, 2023 |
mdpi.com | Nan Zhou |Jianhui Yang
Author / Affiliation / EmailSearch TypeSubmit to this JournalReview for this JournalEdit a Special IssueArticle Menu/ajax/scifeed/subscribeAltmetricshareShareannouncementHelpformat_quoteCitethumb_up... Endorsetextsms... CommentNeed Help? SupportFind support for a specific problem in the support section of our website. Get SupportFeedbackPlease let us know what you think of our products and services. Give FeedbackInformationVisit our dedicated information section to learn more about MDPI.
-
May 12, 2023 |
bpspubs.onlinelibrary.wiley.com | Wei Zhuang |Jiabing Xu |Ye E Wu |Jianhui Yang
Abstract Aims Nirmatrelvir is an antiviral drug with a novel mechanism of action, targeting the 3-CL protease, and is used in the treatment of COVID-19. However, the potential side effects have not yet been fully studied. The aim of this study was to identify potential safety signals of nirmatrelvir by analysing post-marketing safety data based on the largest publicly available worldwide pharmacovigilance database.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →